Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 22.23 0.3 (1.37%) Market Cap: 2.02 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 4.56 GF Score: 39/100

Rocket Pharmaceuticals Inc to Discuss Danon Program Call Transcript

May 10, 2021 / 08:30PM GMT
Release Date Price: $43.35 (-0.96%)
Operator

Welcome to the company update on Danon trial conference call. My name is Vanessa, and I will be your operator for today. (Operator Instructions).

I will now turn the call over to your host, Claudine Prowse, Senior Vice President of Strategy and Corporate Development.

Claudine Prowse
Rocket Pharmaceuticals, Inc. - Senior VP of Strategy and Head of IR & Corporate Development

Thanks, Vanessa. Good afternoon, and thank you all for joining us. The purpose of this call is to share an important update on our Danon disease Phase I clinical trial as discussed this morning with the FDA and disclosed in today's first quarter 2021 financial results press release.

Before we begin, I'd like to remind you that various remarks we will make today constitute forward-looking statements that are qualified by cautionary statements. Please refer to our SEC filings if you have any questions.

Participating on today's call are Dr. Gaurav Shah, Chief Executive Officer; Kinnari Patel, President and Chief Operating Officer; Dr. Jonathan Schwartz, Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot